Clearpoint Neuro Inc (CLPT) FinancialsCLPTClearpoint Neuro Inc

Clearpoint Neuro Inc (CLPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Products: Functional neurosurgery, accounting for 37.2% of total sales, equivalent to $3.43M. Other significant revenue streams include Services: Biologics and drug delivery and Products: Biologics and drug delivery. Understanding this composition is critical for investors evaluating how CLPT navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Clearpoint Neuro Inc maintains a gross margin of 61.67%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -94.15%, while the net margin is -104.20%. These profitability ratios, combined with a Return on Equity (ROE) of -226.52%, provide a clear picture of how effectively CLPT converts its operational activities into shareholder value.

In the context of the broader market, CLPT competes directly with industry leaders such as SGHT and NPCE. With a market capitalization of $467.93M, it holds a significant position in the sector. When comparing efficiency, CLPT's gross margin of 61.67% stands against SGHT's 90.96% and NPCE's 82.83%. Such benchmarking helps identify whether Clearpoint Neuro Inc is trading at a premium or discount relative to its financial performance.

ClearPoint reported Q2 2026 revenue of $10.9 million, an 18% increase year-over-year, with a gross margin of 62%. However, the company has been consistently reporting net losses, with a net income of -$11.3 million in Q2 2026 and a negative net margin of -104.20%.